STOCK TITAN
  1. Home
  2. News
  3. BIOL

Biolase Inc - BIOL STOCK NEWS

Welcome to our dedicated news page for Biolase (Ticker: BIOL), a resource for investors and traders seeking the latest updates and insights on Biolase.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Biolase's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Biolase's position in the market.

News
BIOLASE RECEIVES TOP WORKPLACES 2023 AWARD
Rhea-AI Summary
BIOLASE, Inc. (NASDAQ: BIOL) has been honored with the Top Workplaces 2023 award by Orange County Register Top Workplaces. The award is based on employee feedback and measures 15 culture drivers critical to success. Energage LLC conducted the survey, and Eric Rubino, Energage CEO, emphasized the importance of allowing employees to have a voice and be heard.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.72%
Tags
none
-
News
BIOLASE Successfully Concludes Waterlase iPlus All Tissue Laser Trial
Rhea-AI Summary
BIOLASE, Inc. (NASDAQ: BIOL) announces overwhelmingly positive feedback and unanimous approval for the Waterlase iPlus All Tissue laser during an independently led trial. The trial results demonstrate 100% performance satisfaction and a recommendation for wider adoption among dental practices.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.81%
Tags
none
-
News
BIOLASE, Inc. Announces Pricing of $1.4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Rhea-AI Summary
BIOLASE, Inc. (NASDAQ: BIOL) has entered into a securities purchase agreement to sell approximately $1.4 million of its common stock and pre-funded warrants in a registered direct offering and warrants to purchase common stock in a concurrent private placement. The company intends to use the proceeds for working capital, capital expenditures, product development, and other general corporate purposes, including investments in sales and marketing in the United States and internationally.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.65%
Tags
offering
News
BIOLASE REPORTS THIRD QUARTER FINANCIAL RESULTS; COMPANY BENEFITTING FROM STRATEGIC ACTIONS TAKEN TO STREAMLINE OPERATIONS AND GAIN GREATER OPERATIONAL EFFICIENCIES
Rhea-AI Summary
BIOLASE, Inc. (NASDAQ: BIOL) reported a 9% decrease in net revenue for the third quarter of 2023, with total revenue at $10.9 million. The company experienced a 17% decrease in U.S. laser revenue but a 22% increase in U.S. consumables and other revenue. International laser revenue increased by 5%, while international consumables and other revenue decreased by 16%. Gross margin improved to 34%, and operating expenses decreased by 26% year over year. The company expects full year 2023 revenue to be 1 to 3% higher than full year 2022 revenue, with significantly improved net loss from operations.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-19.58%
Tags
earnings
-
News
Landmark Study Performed by the Independent McGuire Institute Confirms Positive 12 Month Clinical Outcomes for BIOLASE REPAIR® Perio Protocol
Rhea-AI Summary
BIOLASE, Inc. (NASDAQ: BIOL) announced groundbreaking findings from a 12-month follow-up to a clinical trial at The McGuire Institute™, validating BIOLASE REPAIR® Perio Protocol as a superior alternative for treating intrabony periodontal defects. The study compared BIOLASE's protocol to the traditional minimally invasive surgical technique (MIST) and found similar clinical outcomes, enhanced patient experience, safety, minimal invasiveness, and faster recovery.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.33%
Tags
none
-
News
BIOLASE TO REPORT THIRD QUARTER 2023 RESULTS ON NOVEMBER 9, 2023
Rhea-AI Summary
BIOLASE, Inc. (NASDAQ: BIOL) to Release Q3 2023 Financial Results and Host Conference Call on November 9, 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.33%
Tags
conferences earnings
News
BIOLASE Inc. Announces Closing of $4.5 Million Underwritten Public Offering of Series J Convertible Redeemable Preferred Stock and Warrants
Rhea-AI Summary
BIOLASE announces closing of underwritten public offering of 75,000 units at $60.00 per unit. Gross proceeds expected to be approximately $4.5 million. Intends to use net proceeds for working capital and general corporate purposes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.18%
Tags
offering
-
News
BIOLASE Inc. Announces Pricing of $4.5 Million Underwritten Public Offering of Series J Convertible Redeemable Preferred Stock and Warrants
Rhea-AI Summary
BIOLASE announces pricing of public offering of Series J Convertible Preferred Stock and Warrants
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-39.57%
Tags
offering
-
News
BIOLASE REPORTS RECORD CONSUMABLE SALES AS TOTAL SECOND QUARTER REVENUE INCREASES 17% YEAR OVER YEAR
Rhea-AI Summary
BIOLASE reports positive financial results for Q2 2023, with total revenue of $14.3 million, up 17% YoY. Consumable sales reach record $4.1 million, increasing 36% YoY. Gross margin improves to 43%. Company expects improved net income and positive adjusted EBITDA for H2 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-13.87%
Tags
none
News
BIOLASE TO REPORT SECOND QUARTER 2023 RESULTS ON AUGUST 10, 2023
Rhea-AI Summary
BIOLASE, Inc. (NASDAQ: BIOL) to release second quarter 2023 financial and operating results on August 10, 2023, followed by a conference call and webcast to discuss the results and corporate developments. Access the live call by dialing 888-506-0062 (U.S.) or +1 973-528-0011 (International) with access code: 679201.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.44%
Tags
conferences earnings
Stock BIOL logo
Biolase Inc

Nasdaq:BIOL

BIOL Rankings

N/A Ranked by Market Cap
N/A Ranked by Stock Gains
N/A Ranked by Dividends

BIOL Stock Data

4.57M
32.39M
0.34%
8.24%
7.06%
Dental Equipment and Supplies Manufacturing
Manufacturing
Link
US
Irvine

About BIOL

biolase, inc. is a medical device company that develops, manufactures, markets, and sells laser systems in dentistry and medicine and also markets, sells, and distributes dental imaging equipment. biolase’s products are focused on better enabling clinicians to repair and restore patient’s dental conditions while reducing the pain, fear, and anxiety generally associated with dentistry. biolase is committed to elevating the standard of care in dentistry, while enabling clinicians to achieve better business returns.